Page last updated: 2024-12-10

9-deoxy-9,10-didehydro-12,13-didehydro-13,14-dihydroprostaglandin d2

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

9-deoxy-9,10-didehydro-12,13-didehydro-13,14-dihydroprostaglandin D2: PGD2 metabolite in human plasma [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

13,14-dihydro-Delta(12)-prostaglandin J2 : A member of the class of prostaglandins J that is prosta-5,9,12-trien-1-oic acid carrying oxo and hydsroxy substituents at positions 11 and 15 respectively (the 5Z,12E,15S-stereoisomer). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5280885
CHEMBL ID519797
CHEBI ID28130
SCHEMBL ID3368873
MeSH IDM0121330

Synonyms (54)

Synonym
delta(12)-pgj2
13,14-dihydro-delta(12)-prostaglandin j2
CHEBI:28130 ,
9-deoxy-9,10-didehydro-12,13-didehydro-13,14-dihydroprostaglandin d2
(5z,12e,15s)-15-hydroxy-11-oxoprosta-5,9,12-trien-1-oic acid
dddd-pgd2
9-deoxy-delta(9), delta(12)-13,14-dihydroprostaglandin d2
d12-pgj2
9-deoxy-delta(9,12)-13,14-dihydro pgd2
BRD-K83820346-001-02-5
gtpl1876
(z)-7-[(1s,5e)-5-[(3s)-3-hydroxyoctylidene]-4-oxo-1-cyclopent-2-enyl]hept-5-enoic acid
BSPBIO_001284
11-oxo-15s-hydroxy-5z,9z,13e-prostatrienoic acid
LMFA03010020
IDI1_033754
delta-12-prostaglandin j2
delta-12-pgj2
87893-54-7
C05958 ,
delta-12 pgj-2
NCGC00161301-01
NCGC00161301-02
prosta-5,9,12-trien-1-oic acid, 15-hydroxy-11-oxo-, (5z,12e,15s)-
NCGC00161301-03
HMS1989A06
delta12-prostaglandin j2
delta12-pgj2
d12-prostaglandin j2
BML2-B02
HMS1791A06
HMS1361A06
SCHEMBL3368873
CHEMBL519797
(z)-7-[(1s,5e)-5-[(3s)-3-hydroxyoctylidene]-4-oxocyclopent-2-en-1-yl]hept-5-enoic acid
(5z,12e,15s)-15-hydroxy-11-oxo-prosta-5,9,12-trien-1-oic acid
9-deoxy-delta-9,12-pgd2
delta(12)-prostaglandin j2
9-deoxy-delta-9,12-prostaglandin d2
102839-03-2
prosta-5,9,12,13-tetraen-1-oic acid, 15-hydroxy-11-oxo-, (5z,15s)-
delta(12)-pgj(2)
prosta-5,9,12-trien-1-oicacid, 15-hydroxy-11-oxo-, (5z,12e,15s)-
HMS3402A06
Q27077015
SR-01000946874-1
sr-01000946874
delta 12-pgj2 ( delta 12-prostaglandin j2)
nsc783631
nsc-783631
HY-113505
DTXSID901319130
delta12-prostaglandin j2 lipid maps(r) ms standard
CS-0062433
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
antiviral agentA substance that destroys or inhibits replication of viruses.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
prostaglandins J
secondary alcoholA secondary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has two other carbon atoms attached to it.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (48)

PathwayProteinsCompounds
Metabolism14961108
Metabolism of lipids500463
Fatty acid metabolism113203
Arachidonic acid metabolism3682
Synthesis of Prostaglandins (PG) and Thromboxanes (TX)1135
Arachidonic Acid Metabolism2966
Leukotriene C4 Synthesis Deficiency2966
Piroxicam Action Pathway2967
Acetylsalicylic Acid Action Pathway2967
Etodolac Action Pathway2967
Ketoprofen Action Pathway2967
Ibuprofen Action Pathway5076
Rofecoxib Action Pathway2967
Diclofenac Action Pathway2967
Sulindac Action Pathway2967
Celecoxib Action Pathway3573
Ketorolac Action Pathway2967
Suprofen Action Pathway2967
Bromfenac Action Pathway2967
Indomethacin Action Pathway3067
Mefenamic Acid Action Pathway2967
Oxaprozin Action Pathway2967
Nabumetone Action Pathway2967
Naproxen Action Pathway2967
Diflunisal Action Pathway2967
Meloxicam Action Pathway2967
Valdecoxib Action Pathway2967
Antipyrine Action Pathway2967
Antrafenine Action Pathway2967
Carprofen Action Pathway2967
Etoricoxib Action Pathway2967
Fenoprofen Action Pathway2967
Flurbiprofen Action Pathway2967
Magnesium Salicylate Action Pathway2967
Lumiracoxib Action Pathway2967
Lornoxicam Action Pathway2967
Phenylbutazone Action Pathway2967
Nepafenac Action Pathway2967
Trisalicylate-Choline Action Pathway2967
Tolmetin Action Pathway2967
Tiaprofenic Acid Action Pathway2967
Tenoxicam Action Pathway2967
Salsalate Action Pathway2967
Salicylate-Sodium Action Pathway2967
Salicylic Acid Action Pathway2967
Acetaminophen Action Pathway2967
Eicosanoid metabolism via cyclooxygenases (COX)137
Arachidonic acid (AA, ARA) oxylipin metabolism076
Arachidonic acid metabolism via COX (Cyclooxygenase) pathway035

Protein Targets (3)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Microtubule-associated protein tauHomo sapiens (human)Potency25.11890.180013.557439.8107AID1460
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency22.38720.001815.663839.8107AID894
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency42.80000.354828.065989.1251AID504847
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1346377Human DP1 receptor (Prostanoid receptors)1998British journal of pharmacology, Apr, Volume: 123, Issue:7
Characterization of the recombinant human prostanoid DP receptor and identification of L-644,698, a novel selective DP agonist.
AID1346326Human DP2 receptor (Prostanoid receptors)2002British journal of pharmacology, Dec, Volume: 137, Issue:8
Molecular pharmacology of the human prostaglandin D2 receptor, CRTH2.
AID1346401Mouse DP2 receptor (Prostanoid receptors)2003The Journal of pharmacology and experimental therapeutics, Aug, Volume: 306, Issue:2
Expression and molecular pharmacology of the mouse CRTH2 receptor.
AID405533Inhibition of mPGES12008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
Microsomal prostaglandin E2 synthase-1 (mPGES-1): a novel anti-inflammatory therapeutic target.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (50)

TimeframeStudies, This Drug (%)All Drugs %
pre-199011 (22.00)18.7374
1990's25 (50.00)18.2507
2000's11 (22.00)29.6817
2010's3 (6.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.54

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.54 (24.57)
Research Supply Index3.95 (2.92)
Research Growth Index4.49 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.54)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (3.92%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other49 (96.08%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]